Diego Maldonado, MD
Pulmonary Disease · Vero Beach, FLNPI 1568673630
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $208,062 of the $254,182 with a category attached, or 81.9%. 29 manufacturers reported payments, led by GSK at 45.9% of the total. Reporting peaked in 2023 at $77,540 and has fallen 59.2% since, to $31,598 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $665.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$117K
- Actelion Pharmaceuticals US, Inc.$59K
- Mylan Specialty L.p.$29K
- Bayer$27K
- United Therapeutics Corporation$7K
- Intuitive Surgical$5K
- plus $11K from 23 others
What the payments were for
- Consulting fees$12,5795%
- Speaking & faculty fees$208,06282%
- Travel & lodging$16,2256%
- Food & beverage$12,8385%
- Education$4,4772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 99 | $116,764 |
| Actelion Pharmaceuticals US, Inc. | 63 | $59,066 |
| Mylan Specialty L.p. | 54 | $28,566 |
| Bayer | 48 | $27,452 |
| United Therapeutics Corporation | 20 | $6,609 |
| Intuitive Surgical | 14 | $4,700 |
| Pulmonx Corporation | 22 | $4,004 |
| Johnson & Johnson(2 entities) | 13 | $3,753 |
| Veran Medical Technologies, Inc. | 5 | $737 |
| Boston Scientific | 6 | $603 |
| AstraZeneca | 9 | $518 |
| Viatris Specialty LLC | 1 | $337 |
| Amgen | 4 | $182 |
| Verona Pharma, Inc. | 3 | $149 |
| Medical Device Business Services, Inc. | 1 | $114 |
| Pfizer | 1 | $99 |
| Insmed, Inc. | 5 | $84 |
| Inspire Medical Systems, Inc. | 1 | $72 |
| Covidien LP | 1 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $67 |
| Sanofi | 2 | $42 |
| Genentech USA, Inc. | 1 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Penumbra, Inc. | 1 | $24 |
| Merck | 1 | $22 |
| AbbVie | 1 | $21 |
| ICU Medical Inc | 1 | $17 |
| Ambu Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$59,569
- OPSUMIT$59,569
- TRELEGY ELLIPTA$39,061
- Yupelri$28,250
- AREXVY$25,613
- Adempas$25,076
- Da Vinci Surgical System$4,564
- CHARTIS CATHETER$2,983
- ZEPHYR ENDOBRONCHIAL VALVE$2,983
- PULMONX CHARTIS TABLET CONSOLE$2,983
- ZEPHYR DELIVERY CATHETER$2,983
- VELETRI$1,635
- Pulmonx Endobronchial Valve EBV$887
- Spin$609
- GENERAL - THERAPIES$410
- Monarch Platform$380
- MONARCH$364
- NUCALA$125
- Ohtuvayre$125
- TYVASO$124
How this compares
$254,182 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 102 | $1,400,269 |
| OpsumitMacitentan | 102 | $1,310,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 615 | $727,901 |
| UptraviSelexipag | 22 | $540,542 |
| OfevNintedanib Esylate | 36 | $467,648 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 316 | $266,957 |
| Breo ElliptaFluticasone/Vilanterol | 365 | $256,889 |
| Ambrisentan | 48 | $118,929 |
| Pirfenidone | 24 | $106,402 |
| Spiriva RespimatTiotropium Bromide | 56 | $60,524 |
| Incruse ElliptaUmeclidinium Bromide | 77 | $57,651 |
| EliquisApixaban | 45 | $55,091 |
| NucalaMepolizumab | 14 | $52,672 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $33,436 |
| Spiriva HandihalerTiotropium Bromide | 25 | $27,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $59,066 | $1,850,816124 claims |
| BayerAdempas | $27,452 | $1,400,269102 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Nucala | $116,764 | $1,362,0701,387 claims |
| PfizerEliquis | $99 | $55,09145 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $518 | $52,29590 claims |
| MerckDulera | $22 | $6,95712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Vero Beach
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.